Skip to main content
Erschienen in: Surgery Today 8/2016

21.11.2015 | Review Article

Current surgical strategies for malignant pleural mesothelioma

verfasst von: Teruhisa Takuwa, Seiki Hasegawa

Erschienen in: Surgery Today | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Malignant pleural mesothelioma (MPM) is associated with a poor prognosis. The main components of multimodality treatment include surgery, chemotherapy, and radiation therapy. Surgery remains controversial. Two procedures are currently offered: extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). The recent scientific literature suggests that P/D is a well-tolerated procedure, with the potential of becoming a default procedure in multimodality regimens. However, the precise treatment schemes and surgical procedures are yet to be established. In our study, we review the advantages and disadvantages of EPP and P/D, summarize the post-EPP and post-P/D observations (including mortality, morbidity, and median survival time), and discuss the choice of surgical technique (EPP vs. P/D). Moreover, we highlight the aspects of the multimodality treatments that are offered to MPM patients, including chemotherapy, radiotherapy, intensity-modulated radiation therapy, and other types of therapy.
Literatur
1.
Zurück zum Zitat Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg. 2002;22:298–305.CrossRefPubMed Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg. 2002;22:298–305.CrossRefPubMed
2.
Zurück zum Zitat Rusch V, Baldini EH, Bueno R, De Perrot M, Flores R, Hasegawa S, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: Meeting Summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, Mass. J Thora Cardiov Surg. 2013;145:909–10.CrossRef Rusch V, Baldini EH, Bueno R, De Perrot M, Flores R, Hasegawa S, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: Meeting Summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, Mass. J Thora Cardiov Surg. 2013;145:909–10.CrossRef
3.
Zurück zum Zitat Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2006;1:175–6.CrossRef Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2006;1:175–6.CrossRef
4.
Zurück zum Zitat Cameron RB. Extrapleural pneumonectomy is the preferred surgical management in the multimodality therapy of pleural mesothelioma: con argument. Ann Surg Oncol. 2007;14:1249–53.CrossRefPubMed Cameron RB. Extrapleural pneumonectomy is the preferred surgical management in the multimodality therapy of pleural mesothelioma: con argument. Ann Surg Oncol. 2007;14:1249–53.CrossRefPubMed
5.
Zurück zum Zitat Rice D, Rusch VW, Pass H, Asamura H, Nakano T, Edwards J, et al. Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma. A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. Journal of thoracic oncology: official publication of the International Association for the Study of. Lung Cancer. 2011;6:1304–12. Rice D, Rusch VW, Pass H, Asamura H, Nakano T, Edwards J, et al. Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma. A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. Journal of thoracic oncology: official publication of the International Association for the Study of. Lung Cancer. 2011;6:1304–12.
6.
Zurück zum Zitat Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620–626, 626 e621–e623. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620–626, 626 e621–e623.
7.
Zurück zum Zitat Janne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin. 2004;14:567–73.CrossRefPubMed Janne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin. 2004;14:567–73.CrossRefPubMed
8.
Zurück zum Zitat de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:1413–8.CrossRefPubMed de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:1413–8.CrossRefPubMed
9.
Zurück zum Zitat Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7:1631–9.CrossRefPubMed Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7:1631–9.CrossRefPubMed
10.
Zurück zum Zitat de Perrot M, Uy K, Anraku M, Tsao MS, Darling G, Waddell TK, et al. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2007;133:111–6.CrossRefPubMed de Perrot M, Uy K, Anraku M, Tsao MS, Darling G, Waddell TK, et al. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2007;133:111–6.CrossRefPubMed
11.
Zurück zum Zitat Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010;36:1362–9.CrossRefPubMed Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010;36:1362–9.CrossRefPubMed
12.
Zurück zum Zitat Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007–13.CrossRefPubMedPubMedCentral Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007–13.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35:479–95.CrossRefPubMed Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35:479–95.CrossRefPubMed
14.
Zurück zum Zitat Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009;34:17–41.CrossRefPubMed Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009;34:17–41.CrossRefPubMed
15.
Zurück zum Zitat Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication. Semin Thorac Cardiovasc Surg. 2009;21:132–48.CrossRefPubMed Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication. Semin Thorac Cardiovasc Surg. 2009;21:132–48.CrossRefPubMed
16.
Zurück zum Zitat Yan TD, Boyer M, Tin MM, Wong D, Kennedy C, McLean J, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thora Cardiov Surg. 2009;138:619–24.CrossRef Yan TD, Boyer M, Tin MM, Wong D, Kennedy C, McLean J, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thora Cardiov Surg. 2009;138:619–24.CrossRef
17.
Zurück zum Zitat Sugarbaker DJ, Jaklitsch MT, Bueno R, Richards W, Lukanich J, Mentzer SJ, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128:138–46.CrossRefPubMed Sugarbaker DJ, Jaklitsch MT, Bueno R, Richards W, Lukanich J, Mentzer SJ, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128:138–46.CrossRefPubMed
18.
Zurück zum Zitat Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax. 1976;31:15–24.CrossRefPubMedPubMedCentral Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax. 1976;31:15–24.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54–63 (discussion 63–55) Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54–63 (discussion 63–55)
20.
Zurück zum Zitat Rea F, Marulli G, Bortolotti L, Breda C, Favaretto AG, Loreggian L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. Lung Cancer. 2007;57:89–95.CrossRefPubMed Rea F, Marulli G, Bortolotti L, Breda C, Favaretto AG, Loreggian L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. Lung Cancer. 2007;57:89–95.CrossRefPubMed
21.
Zurück zum Zitat Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84:1685–1692 (discussion 1692–1683). Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84:1685–1692 (discussion 1692–1683).
22.
Zurück zum Zitat Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18:1196–202.CrossRefPubMed Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18:1196–202.CrossRefPubMed
23.
Zurück zum Zitat Buduhan G, Menon S, Aye R, Louie B, Mehta V, Vallieres E. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 2009;88:870–875 (discussion 876). Buduhan G, Menon S, Aye R, Louie B, Mehta V, Vallieres E. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 2009;88:870–875 (discussion 876).
24.
Zurück zum Zitat Trousse DS, Avaro JP, D’Journo XB, Doddoli C, Astoul P, Giudicelli R, et al. Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg. 2009;36:759–63.CrossRefPubMed Trousse DS, Avaro JP, D’Journo XB, Doddoli C, Astoul P, Giudicelli R, et al. Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg. 2009;36:759–63.CrossRefPubMed
25.
Zurück zum Zitat Cao CQ, Yan TD, Bannon PG, McCaughan BC. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol. 2010;5:1692–703.CrossRefPubMed Cao CQ, Yan TD, Bannon PG, McCaughan BC. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol. 2010;5:1692–703.CrossRefPubMed
26.
Zurück zum Zitat Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12:763–72.CrossRefPubMedPubMedCentral Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12:763–72.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 2011;12:1093–1094 (author reply 1094–1095). Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 2011;12:1093–1094 (author reply 1094–1095).
28.
Zurück zum Zitat Baldini EH, Recht A, Strauss GM, DeCamp MM Jr, Swanson SJ, Liptay MJ, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1997;63:334–8.CrossRefPubMed Baldini EH, Recht A, Strauss GM, DeCamp MM Jr, Swanson SJ, Liptay MJ, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1997;63:334–8.CrossRefPubMed
29.
Zurück zum Zitat Takuwa T HM, Kuroda A, Matsumoto S, Kondo N, Nakano T, Hasegawa S. Post-recurrence additional chemotherapy is feasible and effective in patients undergoing extrapleural pneumonectomy for malignant pleural mesothelioma. European society for medical oncology conferences 2014;1561P. Takuwa T HM, Kuroda A, Matsumoto S, Kondo N, Nakano T, Hasegawa S. Post-recurrence additional chemotherapy is feasible and effective in patients undergoing extrapleural pneumonectomy for malignant pleural mesothelioma. European society for medical oncology conferences 2014;1561P.
30.
Zurück zum Zitat Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 2011;6:1304–12.CrossRefPubMed Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 2011;6:1304–12.CrossRefPubMed
31.
Zurück zum Zitat Martini N, Bains MS, Beattie EJ Jr. Indications for pleurectomy in malignant effusion. Cancer. 1975;35:734–8.CrossRefPubMed Martini N, Bains MS, Beattie EJ Jr. Indications for pleurectomy in malignant effusion. Cancer. 1975;35:734–8.CrossRefPubMed
32.
Zurück zum Zitat Nakas A, Martin Ucar AE, Edwards JG, Waller DA. The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2008;33:83–8.CrossRefPubMed Nakas A, Martin Ucar AE, Edwards JG, Waller DA. The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2008;33:83–8.CrossRefPubMed
33.
Zurück zum Zitat Ploenes T, Osei-Agyemang T, Krohn A, Waller CF, Duncker-Rohr V, Elze M, et al. Changes in lung function after surgery for mesothelioma. Asian Cardiovasc Thorac Ann. 2013;21:48–55.CrossRefPubMed Ploenes T, Osei-Agyemang T, Krohn A, Waller CF, Duncker-Rohr V, Elze M, et al. Changes in lung function after surgery for mesothelioma. Asian Cardiovasc Thorac Ann. 2013;21:48–55.CrossRefPubMed
34.
Zurück zum Zitat Bolukbas S, Eberlein M, Schirren J. Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. J Thorac Oncol. 2012;7:900–5.CrossRefPubMed Bolukbas S, Eberlein M, Schirren J. Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. J Thorac Oncol. 2012;7:900–5.CrossRefPubMed
35.
Zurück zum Zitat Lang-Lazdunski L, Bille A, Lal R, Cane P, McLean E, Landau D, et al. Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma. J Thorac Oncol. 2012;7:737–43.CrossRefPubMed Lang-Lazdunski L, Bille A, Lal R, Cane P, McLean E, Landau D, et al. Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma. J Thorac Oncol. 2012;7:737–43.CrossRefPubMed
36.
Zurück zum Zitat Hasegawa S. Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg 2014. Hasegawa S. Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg 2014.
37.
Zurück zum Zitat Gupta V, Mychalczak B, Krug L, Flores R, Bains M, Rusch VW, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045–52.CrossRefPubMed Gupta V, Mychalczak B, Krug L, Flores R, Bains M, Rusch VW, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045–52.CrossRefPubMed
38.
Zurück zum Zitat Rusch VW. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest. 1993;103:382S–4S.CrossRefPubMed Rusch VW. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest. 1993;103:382S–4S.CrossRefPubMed
39.
Zurück zum Zitat Steele J. Randomised trial of extended pleurectomy and decortication (EPD) with pemetrexed and platinum chemotherapy versus pemetrexed and platinum alone in patients with malignant pleural mesothelioma (MARS-2) Proc IMIG 2012;12–14 September 2012, Boston 2012. Steele J. Randomised trial of extended pleurectomy and decortication (EPD) with pemetrexed and platinum chemotherapy versus pemetrexed and platinum alone in patients with malignant pleural mesothelioma (MARS-2) Proc IMIG 2012;12–14 September 2012, Boston 2012.
40.
Zurück zum Zitat Datta A, Smith R, Fiorentino F, Treasure T. Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position. Thorax. 2014;69:194–7.CrossRefPubMed Datta A, Smith R, Fiorentino F, Treasure T. Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position. Thorax. 2014;69:194–7.CrossRefPubMed
41.
Zurück zum Zitat Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83:240–5.CrossRefPubMed Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83:240–5.CrossRefPubMed
42.
Zurück zum Zitat Rena O, Casadio C. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: An harmful procedure. Lung Cancer 2012. Rena O, Casadio C. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: An harmful procedure. Lung Cancer 2012.
43.
Zurück zum Zitat Friedberg JS. Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg. 2012;1:472–80.PubMedPubMedCentral Friedberg JS. Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg. 2012;1:472–80.PubMedPubMedCentral
44.
Zurück zum Zitat Rusch V, Baldini EH, Bueno R, De Perrot M, Flores R, Hasegawa S, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston. Mass. J Thorac Cardiovasc Surg. 2013;145:909–10.CrossRefPubMed Rusch V, Baldini EH, Bueno R, De Perrot M, Flores R, Hasegawa S, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston. Mass. J Thorac Cardiovasc Surg. 2013;145:909–10.CrossRefPubMed
45.
Zurück zum Zitat Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.CrossRefPubMed Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.CrossRefPubMed
46.
Zurück zum Zitat Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26:1698–704.CrossRefPubMed Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26:1698–704.CrossRefPubMed
47.
Zurück zum Zitat Lang-Lazdunski L. Surgery for malignant pleural mesothelioma: why, when and what? Lung Cancer. 2014;84:103–9.CrossRefPubMed Lang-Lazdunski L. Surgery for malignant pleural mesothelioma: why, when and what? Lung Cancer. 2014;84:103–9.CrossRefPubMed
48.
Zurück zum Zitat Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, DaSilva MC, Baldini EH, et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013;145:955–63.CrossRefPubMed Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, DaSilva MC, Baldini EH, et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013;145:955–63.CrossRefPubMed
49.
Zurück zum Zitat Van Schil PE, Opitz I, Weder W, De Laet C, Domen A, Lauwers P, et al. Multimodal management of malignant pleural mesothelioma: where are we today? Eur Respir J. 2014;44:754–64.CrossRefPubMed Van Schil PE, Opitz I, Weder W, De Laet C, Domen A, Lauwers P, et al. Multimodal management of malignant pleural mesothelioma: where are we today? Eur Respir J. 2014;44:754–64.CrossRefPubMed
50.
Zurück zum Zitat Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–95.CrossRefPubMed Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–95.CrossRefPubMed
51.
52.
Zurück zum Zitat Stahel R, Alexandros X, Opitz I, Beyeler M, Ochsenbein A, Fruh M et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy (EPP) of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy: Final results of the randomized multicenter phase II trial SAKK17/04. Proffered Paper session, ESMO 2014, 29.09.2014 2014. Stahel R, Alexandros X, Opitz I, Beyeler M, Ochsenbein A, Fruh M et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy (EPP) of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy: Final results of the randomized multicenter phase II trial SAKK17/04. Proffered Paper session, ESMO 2014, 29.09.2014 2014.
53.
Zurück zum Zitat Minatel E, Trovo M, Polesel J, Baresic T, Bearz A, Franchin G, et al. Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. Lung Cancer. 2014;83:78–82.CrossRefPubMed Minatel E, Trovo M, Polesel J, Baresic T, Bearz A, Franchin G, et al. Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. Lung Cancer. 2014;83:78–82.CrossRefPubMed
54.
Zurück zum Zitat Rosenzweig KE, Zauderer MG, Laser B, Krug LM, Yorke E, Sima CS, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2012;83:1278–83.CrossRefPubMedPubMedCentral Rosenzweig KE, Zauderer MG, Laser B, Krug LM, Yorke E, Sima CS, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2012;83:1278–83.CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Study Using Chemotherapy ± Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy, Memorial Slonan Kettering Cancer Center. Clinical Trials. gov Identifier NCT00715611 2015. Study Using Chemotherapy ± Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy, Memorial Slonan Kettering Cancer Center. Clinical Trials. gov Identifier NCT00715611 2015.
56.
Zurück zum Zitat Cho BC, Feld R, Leighl N, Opitz I, Anraku M, Tsao MS, et al. A feasibility study evaluating surgery for mesothelioma after radiation therapy: the “SMART” approach for resectable malignant pleural mesothelioma. J Thorac Oncol. 2014;9:397–402.CrossRefPubMed Cho BC, Feld R, Leighl N, Opitz I, Anraku M, Tsao MS, et al. A feasibility study evaluating surgery for mesothelioma after radiation therapy: the “SMART” approach for resectable malignant pleural mesothelioma. J Thorac Oncol. 2014;9:397–402.CrossRefPubMed
57.
Zurück zum Zitat Ishibashi H, Kobayashi M, Takasaki C, Okubo K. Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy. Gen Thorac Cardiovasc Surg 2015. Ishibashi H, Kobayashi M, Takasaki C, Okubo K. Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy. Gen Thorac Cardiovasc Surg 2015.
58.
Zurück zum Zitat Sugarbaker PH, Stuart OA, Eger C. Pharmacokinetics of Hyperthermic Intrathoracic Chemotherapy following Pleurectomy and Decortication. Gastroenterol Res Pract. 2012;2012:471205.PubMedPubMedCentral Sugarbaker PH, Stuart OA, Eger C. Pharmacokinetics of Hyperthermic Intrathoracic Chemotherapy following Pleurectomy and Decortication. Gastroenterol Res Pract. 2012;2012:471205.PubMedPubMedCentral
59.
Zurück zum Zitat Ried M, Potzger T, Braune N, Diez C, Neu R, Sziklavari Z, et al. Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies. J Surg Oncol. 2013;107:735–40.CrossRefPubMed Ried M, Potzger T, Braune N, Diez C, Neu R, Sziklavari Z, et al. Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies. J Surg Oncol. 2013;107:735–40.CrossRefPubMed
60.
Zurück zum Zitat Ried M, Potzger T, Braune N, Neu R, Zausig Y, Schalke B, et al. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience. Eur J Cardiothorac Surg. 2013;43:801–7.CrossRefPubMed Ried M, Potzger T, Braune N, Neu R, Zausig Y, Schalke B, et al. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience. Eur J Cardiothorac Surg. 2013;43:801–7.CrossRefPubMed
61.
Zurück zum Zitat Richards WG, Zellos L, Bueno R, Jaklitsch MT, Janne PA, Chirieac LR, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24:1561–7.CrossRefPubMed Richards WG, Zellos L, Bueno R, Jaklitsch MT, Janne PA, Chirieac LR, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24:1561–7.CrossRefPubMed
62.
Zurück zum Zitat Martin-Ucar AE, Edwards JG, Rengajaran A, Muller S, Waller DA. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur J Cardiothorac Surg. 2001;20:1117–21.CrossRefPubMed Martin-Ucar AE, Edwards JG, Rengajaran A, Muller S, Waller DA. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur J Cardiothorac Surg. 2001;20:1117–21.CrossRefPubMed
63.
Zurück zum Zitat Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384:1118–27.CrossRefPubMed Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384:1118–27.CrossRefPubMed
Metadaten
Titel
Current surgical strategies for malignant pleural mesothelioma
verfasst von
Teruhisa Takuwa
Seiki Hasegawa
Publikationsdatum
21.11.2015
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 8/2016
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-015-1275-3

Weitere Artikel der Ausgabe 8/2016

Surgery Today 8/2016 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.